Mark Lewis: After KEYNOTE-177 every patient with metastatic colon cancer should have MMR testing at the very least to assess their candidacy for immunotherapy.

Mark Lewis, Director and GI Oncology at Intermountain Healthcare, shared a post by The Oncologist, adding the following:

“After KEYNOTE-177 every patient with metastatic colon cancer should have MMR testing at the very least to assess their candidacy for immunotherapy. We almost never treat breast cancer without knowing receptor status and other solid tumors merit biomarker-informed care too!”

Quoting The Oncologist’s post:

“According to the results of this web-based survey, oncologists from rural areas and urban clusters were familiar with biomarker testing in mCRC. However, reported biomarker testing is still suboptimal based on guideline recommendations.”

For details click here
Source: Mark Lewis/Twitter and The Oncologist/Twitter